Casi Pharmaceuticals Stock Current Valuation
| CASI Stock | USD 2.36 0.02 0.85% |
Valuation analysis of CASI Pharmaceuticals helps investors to measure CASI Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. The current Enterprise Value Over EBITDA is estimated to decrease to -1.57. The current Enterprise Value Multiple is estimated to decrease to -1.57. Fundamental drivers impacting CASI Pharmaceuticals' valuation include:
Overvalued
Today
Please note that CASI Pharmaceuticals' price fluctuation is extremely dangerous at this time. Calculation of the real value of CASI Pharmaceuticals is based on 3 months time horizon. Increasing CASI Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since CASI Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of CASI Stock. However, CASI Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.36 | Real 1.76 | Target 4.0 | Hype 2.36 |
The intrinsic value of CASI Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence CASI Pharmaceuticals' stock price.
Estimating the potential upside or downside of CASI Pharmaceuticals helps investors to forecast how CASI stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of CASI Pharmaceuticals more accurately as focusing exclusively on CASI Pharmaceuticals' fundamentals will not take into account other important factors: CASI Pharmaceuticals Company Current Valuation Analysis
CASI Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current CASI Pharmaceuticals Current Valuation | 48.23 M |
Most of CASI Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CASI Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
CASI Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for CASI Pharmaceuticals is extremely important. It helps to project a fair market value of CASI Stock properly, considering its historical fundamentals such as Current Valuation. Since CASI Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of CASI Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of CASI Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, CASI Pharmaceuticals has a Current Valuation of 48.23 M. This is 99.66% lower than that of the Biotechnology sector and 98.96% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.71% higher than that of the company.
CASI Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CASI Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CASI Pharmaceuticals could also be used in its relative valuation, which is a method of valuing CASI Pharmaceuticals by comparing valuation metrics of similar companies.CASI Pharmaceuticals is currently under evaluation in current valuation category among its peers.
CASI Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, CASI Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to CASI Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
CASI Fundamentals
| Return On Equity | -10.94 | ||||
| Return On Asset | -0.63 | ||||
| Profit Margin | (1.49) % | ||||
| Operating Margin | (2.57) % | ||||
| Current Valuation | 48.23 M | ||||
| Shares Outstanding | 15.49 M | ||||
| Shares Owned By Insiders | 48.38 % | ||||
| Shares Owned By Institutions | 20.42 % | ||||
| Number Of Shares Shorted | 303.48 K | ||||
| Price To Earning | (16.46) X | ||||
| Price To Book | 11.21 X | ||||
| Price To Sales | 1.15 X | ||||
| Revenue | 28.54 M | ||||
| Gross Profit | 12.95 M | ||||
| EBITDA | (34.87 M) | ||||
| Net Income | (39.26 M) | ||||
| Cash And Equivalents | 24.57 M | ||||
| Cash Per Share | 1.81 X | ||||
| Total Debt | 22.14 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 3.21 X | ||||
| Book Value Per Share | (1.31) X | ||||
| Cash Flow From Operations | (29.22 M) | ||||
| Short Ratio | 0.10 X | ||||
| Earnings Per Share | (2.89) X | ||||
| Target Price | 4.0 | ||||
| Number Of Employees | 233 | ||||
| Beta | 0.72 | ||||
| Market Capitalization | 36.25 M | ||||
| Total Asset | 53.67 M | ||||
| Retained Earnings | (700.08 M) | ||||
| Working Capital | 3.12 M | ||||
| Current Asset | 17.15 M | ||||
| Current Liabilities | 3.51 M | ||||
| Net Asset | 53.67 M |
About CASI Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CASI Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CASI Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CASI Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| NOAH | Noah Holdings | |
| CIG | Companhia Energetica de | |
| BBVA | Banco Bilbao Viscaya | |
| ENIC | Enel Chile SA | |
| SBSW | Sibanye Gold Ltd |
Check out CASI Pharmaceuticals Piotroski F Score and CASI Pharmaceuticals Altman Z Score analysis. For more detail on how to invest in CASI Stock please use our How to Invest in CASI Pharmaceuticals guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CASI Pharmaceuticals. If investors know CASI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CASI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.89) | Revenue Per Share | Quarterly Revenue Growth 0.049 | Return On Assets | Return On Equity |
The market value of CASI Pharmaceuticals is measured differently than its book value, which is the value of CASI that is recorded on the company's balance sheet. Investors also form their own opinion of CASI Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is CASI Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CASI Pharmaceuticals' market value can be influenced by many factors that don't directly affect CASI Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CASI Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if CASI Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CASI Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.